Pliant snags $287.5 million in oversubscribed public offering amid market uncertainty
Pliant Therapeutics' recent fundraise to boost its rare disease pipeline comes when experts predict a challenging public market.
Qurient partners with TB Alliance to develop telacebec
Race to the finish: pharma edges closer to approval with RSV vaccines
Sanofi offers refunds for Cablivi in novel model for rebates
US FDA approves GSK’s Jesduvroq to treat anaemia of CKD
Pfizer reports 30% operational growth in full-year 2022 revenues
Analysis
View More
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Themes
View MoreChina’s NMPA conditionally approves two oral drugs for Covid-19
The Xiannuoxin and VV116 oral small-molecule drugs are developed to treat mild to moderate Covid-19 adult patients.
More themes
Insights
View MoreMerck reports 2% increase in worldwide sales in Q4 2022
Merck recorded a 1% rise in pharmaceutical sales to $12.18bn compared to $12.03bn in the prior-year quarter.
More Insights
Who’s hiring who? Hiring activity related to robotics increased by 11% in the pharmaceutical industry in Q3 2022
Who’s hiring who? Hiring activity related to social responsibility increased by 10% in the pharmaceutical industry in Q3 2022
Who’s hiring who? Hiring activity related to artificial intelligence increased by 7% in the pharmaceutical industry in Q3 2022
Who’s hiring who? Hiring activity related to cloud decreased by 8% in the pharmaceutical industry in Q3 2022
Buyer's Guides
View More
GlobalData Reports
View More
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Health Canada accepts Veru’s Covid-19 therapy NDS-CV for review
South Korea authorises Novavax Covid-19 vaccine as booster dose
BioNTech to buy UK-based AI company InstaDeep
India’s Hetero receives WHO approval for Nirmacom to treat Covid-19